EcoDrugPlus

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSCPOG00000001972
Gene Symbol: HTR6
4 Cross references
115 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSCPOG00000007482
Gene Symbol: HTR7
2 Cross references
221 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSCPOG00000013107
Gene Symbol: ARAF
2 Cross references
192 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSCPOG00000005903
Gene Symbol: ABL1
4 Cross references
204 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSCPOG00000011313
Gene Symbol: ADAM17
2 Cross references
283 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSCPOG00000009911
Gene Symbol: ADAMTS5
2 Cross references
199 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSCPOG00000009588
Gene Symbol: ADRM1
4 Cross references
261 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSCPOG00000004489
Gene Symbol: AKT1
4 Cross references
220 Possible Orthologues:

Akt Serine/threonine Kinase 2

Ensembl ID : ENSCPOG00000011831
Gene Symbol: AKT2
2 Cross references
257 Possible Orthologues:

Akt Serine/threonine Kinase 3

Ensembl ID : ENSCPOG00000015504
Gene Symbol: AKT3
2 Cross references
201 Possible Orthologues:

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSCPOG00000008234
Gene Symbol: ALK
2 Cross references
195 Possible Orthologues:

Atp Binding Cassette Subfamily B Member 1

Ensembl ID : ENSCPOG00000012422
Gene Symbol: ABCB1
3 Cross references
153 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).